To explore the clinical relevance of the β-catenin:MSI2 association, we screened 20 AML patients for protein expression of MSI2 and β-catenin (patient clinical details provided in Supplementary Table S1). This evidence concerns the gene MSI2 and acute myeloid leukemia.